Rinvoq – Health

FDA’s new JAK safety restrictions spell trouble for AbbVie’s Rinvoq, but to what extent?

AbbVie’s megablockbuster Rinvoq ambition suffered a blow thanks to an updated safety warning and treatment restriction from the FDA. But pharma watchers have different opinions on just how significant the impact will be on AbbVie’s JAK inhibitor. In an announcement Wednesday, the FDA is revising Rinvoq’s boxed warning to include information about increased risks of… Read More »

AbbVie pegs growth to booming Skyrizi, Rinvoq in post-merger future. But neurology could be a ‘sleeper’

With its $ 63 billion merger with Allergan in the rearview, the new AbbVie is facing a major challenge as U.S. biosimilars for Humira cast a pall over the near-term future. But AbbVie figures its homegrown prospects will keep driving growth—and a couple of surprises from Allergan could make the forecast even rosier. After six… Read More »